Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TransMolecular names new president and CEO
Prior to joining TransMolecular, Mr Radie was executive vice president and chief business officer at Prestwick Pharmaceuticals, and vice president of project management and chief business officer at
Prior to joining TransMolecular, Mr Radie was executive vice president and chief business officer at Prestwick Pharmaceuticals, and vice president of project management and chief business officer at
Dr Lord comes to Navigenics from Louisville, Kentucky-based Humana, where as chief innovation officer he was responsible for designing new products and services to enable people to navigate
Dr Sable has served as resident and chief resident in obstetrics and gynecology at New York Hospital-Cornell Medical Center and as fellow in reproductive endocrinology at the Brigham
Mr Wolcott most recently served as president and COO of Dimicron, a medical company utilizing synthetic diamond for orthopedic applications, and previously as COO and director of Rubicon
Under the terms of the licensing agreement, BioWa grants Sanofi-Aventis non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through Potelligent technology for an undisclosed number of
Mr Davis brings over 25 years of experience in global healthcare and medical devices markets and over 14 of those in the ophthalmic arena to Paradigm Medical Industries.
Under the terms of the agreement, Lantheus acquired the US, including Puerto Rico, Canadian, and Australian rights to MS-325 from Epix. Epix will continue to own European and
Pfizer has discontinued the SUN 1107 Phase III study of Sutent in advanced breast cancer based on statistical assessment for futility. SUN 1107 evaluated single-agent sunitinib versus single-agent
Participating in the company’s second funding round were Emergent Medical Partners, Saints Capital, Mitsubishi International, and Fog City Fund plus several private individuals. Jill Anderson, president and CEO
According to Covance, the new offices and expanded facilities in Latin America will help the company expedite the execution of clinical studies with a full range of services,